Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07667803 · ClinicalTrials.gov registry record · Phase 3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
A Phase 3 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 4,500
- Enrollment target
NCT07667803 is a Phase 3 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 4,500 participants.
The verdict
NCT07667803, a Phase 3 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 4,500 participants
- Enrollment target
Study Summary
This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).
Interventions
- DRUG Placebo
- DRUG Elecoglipron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,500 participants |
| Start Date | 2026-06-29 |
| Est. Completion | 2029-07-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07667803
The ClinicalTrials.gov registry entry for NCT07667803 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 4,500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07667803 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07667803 about?
NCT07667803 is a clinical study titled "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM". This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exerci...
What is the current status of trial NCT07667803?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 4,500 participants. The study started on 2026-06-29. Estimated completion is 2029-07-30.
What interventions are being tested in trial NCT07667803?
The interventions under investigation include: Placebo (DRUG), Elecoglipron (DRUG).
Who is sponsoring clinical trial NCT07667803?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.